Drug Type AAV based gene therapy |
Synonyms HORA RPE65, HORA-RPE65 |
Target |
Mechanism RPE65 gene transference |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Coave TherapeuticsStartup |
Active Organization Coave TherapeuticsStartup |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Retinitis Pigmentosa | Phase 2 | FR | Coave TherapeuticsStartup | 20 Nov 2018 |
Leber Congenital Amaurosis | Phase 2 | FR | Coave TherapeuticsStartup | 12 Dec 2014 |